Literature DB >> 7530506

Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis.

Y Shima1, N Nishimoto, A Ogata, Y Fujii, K Yoshizaki, T Kishimoto.   

Abstract

To find out which cytokines are involved in the pathogenesis of multiple myeloma, we investigated cytokine receptor expression on myeloma cells using a panel of monoclonal antibodies (MoAbs). Flow cytometric analysis of five myeloma cell lines (RPMI8226, ARH77, KMM-1, U266, and Hs) and myeloma cells freshly isolated from eight patients showed that interleukin-1 receptor (IL-1R) type I and type II, IL-2R alpha and beta chains, IL-4R, IL-6R, IL-7R, IL-8R, granulocyte macrophage colony-stimulating factor receptor (GM-CSFR), c-kit (stem cell factor receptor [SCFR]), membrane bound stem cell factor (MBSCF), and tumor necrosis factor (TNF) receptors type I and type II were not always detected on the myeloma cells. However, interferon-gamma receptor, gp130, and Fas antigen were constitutively expressed, except one sample. To determine the role of Fas antigen on myeloma cells, these cells were cultured with anti-Fas MoAb. Apoptotic changes characterized by loss of cell volume, membrane blebbing, fragmentation of nuclei, and condensed chromatin were observed in three of five myeloma cell lines. When bcl-2 expression was examined, it was seen in all the cell lines regardless of the sensitivity to anti-Fas MoAb. Furthermore, anti-Fas MoAb not only induced apoptosis of freshly isolated myeloma cells but also inhibited the DNA synthesis, although such effects varied from patient to patient. The data indicate that only some myeloma cells undergo apoptosis in response to the signal mediated by the Fas antigen.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7530506

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus.

Authors:  L C Spender; E J Cannell; M Hollyoake; B Wensing; J M Gawn; M Brimmell; G Packham; P J Farrell
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 2.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

Review 3.  The Fas counterattack: a molecular mechanism of tumor immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J K Collins; F Shanahan
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

Review 4.  Fas expression and apoptosis in human B cells.

Authors:  E Schattner; S M Friedman
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

5.  Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease.

Authors:  P L Nguyen; N L Harris; J Ritz; M J Robertson
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

6.  IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.

Authors:  T Teshima; G R Hill; L Pan; Y S Brinson; M R van den Brink; K R Cooke; J L Ferrara
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

7.  Increased expression but not sensitivity to Fas/CD95 in glioblastoma cells depleted of mitochondrial DNA.

Authors:  Bertrand C Liang
Journal:  Exp Ther Med       Date:  2010-09-29       Impact factor: 2.447

8.  Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells.

Authors:  M A Frassanito; F Silvestris; N Silvestris; P Cafforio; G Camarda; G Iodice; F Dammacco
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

9.  The distribution and intracellular location of Fas and Fas Ligand following gastric carcinogenesis: Fas Ligand expressing gastric carcinoma cells can inhibit local immune response.

Authors:  Huanran Liu; Hideyuki Ubukata; Takanobu Tabuchi; Takeshi Nakachi; Hiroyuki Nagata; Jiro Shimazaki; Gyou Motohashi; Satoru Konishi; Motoi Nishimura; Tetsuro Satani; JianWei Hong; Ichiro Nakada; Abbi R Saniabadi; Takafumi Tabuchi
Journal:  Mol Cell Biochem       Date:  2009-05-21       Impact factor: 3.396

10.  Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma.

Authors:  Amorette Barber; Tong Zhang; Christina J Megli; Jillian Wu; Kenneth R Meehan; Charles L Sentman
Journal:  Exp Hematol       Date:  2008-07-02       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.